Drug intelligence / Profile preview

Triclosan

Development stage
Phase 4
Modality
Small Molecules
Administration
Topical, Oral
01

Overview

Triclosan is a synthetic broad-spectrum antimicrobial and antifungal agent widely used in personal care products (such as soaps, toothpaste, mouthwash), household items (like plastic chopping boards and sports equipment), and healthcare settings for disinfection and infection control. Developed in 1966, it acts primarily by inhibiting the bacterial enzyme enoyl-acyl carrier protein reductase (FabI), which is essential for fatty acid biosynthesis in bacteria. At lower concentrations it is bacteriostatic; at higher concentrations it can be bactericidal through additional mechanisms including membrane disruption. Triclosan does not affect humans via this mechanism because humans lack the FabI enzyme. It has been used to reduce methicillin-resistant Staphylococcus aureus (MRSA) colonization and is incorporated into surgical scrubs and sutures to reduce surgical site infections. Its widespread use has raised concerns about potential health risks such as endocrine disruption, bacterial resistance development, allergies, skin irritation, reproductive effects, and environmental impact[1][5][6][8].

Brand names
DermaprotTriclotrex-BTing
Other names
2,4,4-trichloro-2-hydroxydiphenyl ether
02

Targets

InhA

Beyond the preview

Go deeper on Triclosan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triclosan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call